AN ELABORATIVE STUDY ON DIPEPTIDYL PEPTIDASE-IV INHIBITORS IN THE MANAGEMENT OF DIABETES
Gaurav Kayal* and Snehlata Kayal
Type-2 diabetes mellitus is a metabolic disorder due to insulin resistance, reduced insulin sensitivity or reduced insulin secretion. This form of diabetes is commonly treated with a range of drugs designed to increase insulin production, decrease insulin resistance, decrease glucose production by the liver or slow intestinal absorption of carbohydrates. One recent advance in the management of type 2 diabetes has been the development and clinical use of DPP-4 inhibitors. The development of this class of drug was based upon observations from the early twentieth century when it was noted that factors secreted from the gut participated in the regulation of pancreatic endocrine secretion. These factors were collectively termed 'incretins'. Several drugs are presently available to reduce hyperglycemia such as sulfonylureas and biguanids. These drugs have various side effects as reported in literatures and thus searching for a new class of compounds is essential to overcome these problems. The purpose of this study is to review the Anti-Diabetic potentials of various DPP-IV inhibitors and to generate a comparative SAR that may support to improve their anti-hyperglycaemic activity by newer and potent diverse structural modifications of synthesized derivatives.
Keywords: DPP-IV inhibitors, structural diversity, anti-hyperglycaemic activity.
[Full Text Article]